Physiological consequences of phasic insulin release in the normal animal
Open accessAbstract
The dose-response relationship between the hepatic sinusoidal insulin level and glucose production by the liver is such that a half-maximally effective concentration is at or slightly below the hormone levels seen basally after an overnight fast. In the normal individual, the direct effect of the hormone on the hepatocyte is far more important in restraining glucose production than its indirect effect mediated via a suppression of lipolysis. Because insulin regulates the liver in a direct fashion, its effect occurs within several minutes. Thus, the speed with which insulin works and the sensitivity of the liver to it predict that first-phase insulin release should have a significant effect in quickly suppressing hepatic glucose production. On the other hand, nonhepatic tissues are much less sensitive to insulin and respond slowly as a result of the need for insulin to cross the endothelial barrier. As a result, first-phase insulin is unlikely to significantly alter peripheral glucose disposal. Simulation studies in humans and dogs in which the effects of first-phase insulin were simulated confirmed the aforementioned predictions. In addition, they confirmed the ability of second-phase insulin release to have significant effects on both glucose production and utilization.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
First-phase insulin secretion serves to rapidly inhibit hepatic glucose production.
“First-phase insulin secretion serves to rapidly inhibit hepatic glucose production (31).”
From Melatonin Impairs Glucose Tolerance, First-Phase Insulin Secretion, and Insulin Feedback Inhibition; Interaction With <i>MTNR1B</i> Diabetes Risk Variant (2026) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
No references could be resolved yet.
Research works printed but not linked: 1
- Cherrington AD: Control of glucose production in vivo by insulin and glucagon. In The Handbook of Physiology: The Endocrine Pancreas and Metabolic Regulation. Jefferson LS, Cherrington AD, Eds. New York, Oxford Press, 2001, p. 759 -785
Cited by
Sorted by citations
Li, J., Kuang, Y., & Mason, C. C. (2006) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2006.04.002 · Cited by 241 · see citing works
Analysis of a model of the glucose-insulin regulatory system with two delays
Li, J., & Kuang, Y. (2007) · SIAM Journal on Applied Mathematics · doi:10.1137/050634001 · Cited by 96 · see citing works
Qian, J., Stefanovski, D., Andersen, P. A. K., Vujovic, N., Kelly, L., Lepson, J., Nguyen, H., Byrne, S., Wang, W., Mandrup-Poulsen, T., et al. (2026) · Diabetes Care · doi:10.2337/dc26-0164
- Authors
- Cherrington, A. D., Sindelar, D., Edgerton, D., Steiner, K., & McGuinness, O. P.
- Affiliations
- Vanderbilt University (US)
- Eli Lilly (United States) (US)
- Wyeth (US)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2002-02-01
- Volume
- 51
- Issue
- suppl_1
- Pages
- S103-S108
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2107837467
- Cited by
- 63
- References
- 0
- Citations by year
- 2026: 1 · 2021: 5 · 2020: 1 · 2019: 3 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 2 · 2014: 1 · 2013: 3 · 2012: 3
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p60dk020593-31)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 18243, DK43706, DK 20593, 5P60 DK-20593)
- Topics
- Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- first-phase insulin release, second-phase insulin release, hepatic glucose production, insulin sensitivity, hepatic insulin action, endothelial barrier, glucose metabolism, simulation study
- MeSH terms
- Insulin Secretion, Animals, Blood Glucose, Insulin, Liver
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review